QQQ   354.84 (-0.02%)
AAPL   179.21 (-0.21%)
MSFT   333.68 (-0.67%)
META   271.12 (-0.10%)
GOOGL   127.31 (+1.03%)
AMZN   126.61 (+1.05%)
TSLA   221.31 (+1.70%)
NVDA   386.54 (-1.32%)
NIO   7.87 (+2.61%)
BABA   86.69 (+2.71%)
AMD   124.23 (+5.34%)
T   15.66 (+1.75%)
F   12.93 (+2.70%)
MU   67.54 (-0.34%)
CGC   0.74 (-5.13%)
GE   105.46 (+1.31%)
DIS   92.16 (+1.27%)
AMC   4.64 (+0.22%)
PFE   38.37 (-0.72%)
PYPL   65.02 (+0.79%)
NFLX   399.29 (-1.05%)
QQQ   354.84 (-0.02%)
AAPL   179.21 (-0.21%)
MSFT   333.68 (-0.67%)
META   271.12 (-0.10%)
GOOGL   127.31 (+1.03%)
AMZN   126.61 (+1.05%)
TSLA   221.31 (+1.70%)
NVDA   386.54 (-1.32%)
NIO   7.87 (+2.61%)
BABA   86.69 (+2.71%)
AMD   124.23 (+5.34%)
T   15.66 (+1.75%)
F   12.93 (+2.70%)
MU   67.54 (-0.34%)
CGC   0.74 (-5.13%)
GE   105.46 (+1.31%)
DIS   92.16 (+1.27%)
AMC   4.64 (+0.22%)
PFE   38.37 (-0.72%)
PYPL   65.02 (+0.79%)
NFLX   399.29 (-1.05%)
QQQ   354.84 (-0.02%)
AAPL   179.21 (-0.21%)
MSFT   333.68 (-0.67%)
META   271.12 (-0.10%)
GOOGL   127.31 (+1.03%)
AMZN   126.61 (+1.05%)
TSLA   221.31 (+1.70%)
NVDA   386.54 (-1.32%)
NIO   7.87 (+2.61%)
BABA   86.69 (+2.71%)
AMD   124.23 (+5.34%)
T   15.66 (+1.75%)
F   12.93 (+2.70%)
MU   67.54 (-0.34%)
CGC   0.74 (-5.13%)
GE   105.46 (+1.31%)
DIS   92.16 (+1.27%)
AMC   4.64 (+0.22%)
PFE   38.37 (-0.72%)
PYPL   65.02 (+0.79%)
NFLX   399.29 (-1.05%)
QQQ   354.84 (-0.02%)
AAPL   179.21 (-0.21%)
MSFT   333.68 (-0.67%)
META   271.12 (-0.10%)
GOOGL   127.31 (+1.03%)
AMZN   126.61 (+1.05%)
TSLA   221.31 (+1.70%)
NVDA   386.54 (-1.32%)
NIO   7.87 (+2.61%)
BABA   86.69 (+2.71%)
AMD   124.23 (+5.34%)
T   15.66 (+1.75%)
F   12.93 (+2.70%)
MU   67.54 (-0.34%)
CGC   0.74 (-5.13%)
GE   105.46 (+1.31%)
DIS   92.16 (+1.27%)
AMC   4.64 (+0.22%)
PFE   38.37 (-0.72%)
PYPL   65.02 (+0.79%)
NFLX   399.29 (-1.05%)
NASDAQ:INKT

MiNK Therapeutics (INKT) Stock Forecast, Price & News

$1.92
+0.10 (+5.49%)
(As of 06/6/2023 ET)
Compare
Today's Range
$1.82
▼
$1.95
50-Day Range
$0.89
▼
$2.27
52-Week Range
$0.85
▼
$4.32
Volume
46,383 shs
Average Volume
83,116 shs
Market Capitalization
$66.09 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$5.00
ProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesSEC FilingsShort InterestSocial Media

MiNK Therapeutics MarketRank™ Forecast

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
160.4% Upside
$5.00 Price Target
Short Interest
Healthy
1.93% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
N/A
Insider Trading
Acquiring Shares
$362,492 Bought Last Quarter
Proj. Earnings Growth
Decreasing
From ($0.75) to ($0.76) Per Share

Overall MarketRank™

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

1.84 out of 5 stars

Medical Sector

678th out of 981 stocks

Biological Products, Except Diagnostic Industry

107th out of 155 stocks

See Top Rated MarketRank™ Stocks Here

INKT stock logo

About MiNK Therapeutics (NASDAQ:INKT) Stock

MiNK Therapeutics, Inc., a clinical stage biopharmaceutical company, engages in the discovery, development, and commercialization of allogeneic, off-the-shelf, invariant natural killer T (iNKT) cell therapies to treat cancer and other immune-mediated diseases. Its product candidate is AGENT-797, an off-the-shelf, allogeneic for iNKT cell therapy and treatment of various myeloma diseases, which is in Phase 1 clinical trials. The company was formerly known as AgenTus Therapeutics, Inc. MiNK Therapeutics, Inc. was incorporated in 2017 and is based in New York, New York. MiNK Therapeutics, Inc. operates as a subsidiary of Agenus Inc.

Receive INKT Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for MiNK Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

INKT Stock News Headlines

May 23, 2023 | cbsnews.com
"Off-the-shelf" cell therapy shows promise for cancers resistant to current treatments, including immunotherapies
May 22, 2023 | finance.yahoo.com
MiNK Presents Clinical Data on Allogeneic iNKT Cells (agenT-797) in Severe Respiratory Distress at the American Thoracic Society International Conference
June 6, 2023 | Behind the Markets (Ad)
66,000% upside on tiny biotech?
The Wall Street Journal reports that this medical breakthrough is "Transforming Medicine." One analyst calculated that it could be worth $1 Trillion, making the upside potential of this small-cap 66,000% above today's price.
May 18, 2023 | markets.businessinsider.com
B.Riley Financial Sticks to Their Buy Rating for MiNK Therapeutics (INKT)
May 18, 2023 | finance.yahoo.com
MiNK's Novel FAP-CAR-iNKT Presented at ASGCT
May 16, 2023 | americanbankingnews.com
MiNK Therapeutics (NASDAQ:INKT) Rating Reiterated by B. Riley
May 16, 2023 | americanbankingnews.com
MiNK Therapeutics (NASDAQ:INKT) Given "Buy" Rating at B. Riley
May 15, 2023 | markets.businessinsider.com
Robert W. Baird Reaffirms Their Buy Rating on MiNK Therapeutics (INKT)
June 6, 2023 | Behind the Markets (Ad)
Laser breakthrough could send stock soaring 2,467%
Laser breakthrough could send stock soaring 2,476% Whenever the military develops a breakthrough technology, timely investors could see groundbreaking returns. General Dynamics returned 8,990%... Boeing soared 4,238%... L3Harris shot up 1,628%...
May 14, 2023 | americanbankingnews.com
Agenus Inc Acquires 22,065 Shares of MiNK Therapeutics, Inc. (NASDAQ:INKT) Stock
May 12, 2023 | msn.com
Recap: MiNK Therapeutics Q1 Earnings
May 12, 2023 | msn.com
The Latest Analyst Ratings for MiNK Therapeutics
May 12, 2023 | markets.businessinsider.com
MiNK Therapeutics (INKT) Has a New Rating from H.C. Wainwright
May 12, 2023 | markets.businessinsider.com
B.Riley Financial Keeps Their Buy Rating on MiNK Therapeutics (INKT)
May 11, 2023 | finance.yahoo.com
MiNK Therapeutics Reports Corporate Update and First Quarter 2023 Financial Results
May 9, 2023 | americanbankingnews.com
MiNK Therapeutics (INKT) Scheduled to Post Quarterly Earnings on Thursday
May 8, 2023 | americanbankingnews.com
Insider Selling: MiNK Therapeutics, Inc. (NASDAQ:INKT) Director Sells $95,000.00 in Stock
May 8, 2023 | americanbankingnews.com
Insider Buying: MiNK Therapeutics, Inc. (NASDAQ:INKT) Major Shareholder Acquires $95,190.00 in Stock
May 8, 2023 | americanbankingnews.com
MiNK Therapeutics, Inc. (NASDAQ:INKT) Major Shareholder Buys $138,984.12 in Stock
May 7, 2023 | americanbankingnews.com
MiNK Therapeutics, Inc. (NASDAQ:INKT) Director Purchases $95,000.00 in Stock
April 27, 2023 | finance.yahoo.com
MiNK Therapeutics to Report First Quarter 2023 Corporate Update and Financial Results
April 23, 2023 | americanbankingnews.com
MiNK Therapeutics (NASDAQ:INKT) Given Buy Rating at HC Wainwright
April 21, 2023 | markets.businessinsider.com
Robert W. Baird Keeps Their Buy Rating on MiNK Therapeutics (INKT)
April 18, 2023 | finance.yahoo.com
MiNK Therapeutics Announces Clinical Data of Allogeneic iNKT Cells (agenT-797) in Solid Tumor Cancers at the AACR Annual Meeting
April 16, 2023 | finance.yahoo.com
We're Keeping An Eye On MiNK Therapeutics' (NASDAQ:INKT) Cash Burn Rate
April 4, 2023 | finance.yahoo.com
MiNK Therapeutics, Inc. (INKT) Could Find a Support Soon, Here's Why You Should Buy the Stock Now
March 30, 2023 | finance.yahoo.com
Agenus Announces Dividend of 5 Million Shares of MiNK Therapeutics
See More Headlines

INKT Price History

INKT Company Calendar

Last Earnings
3/21/2023
Today
6/06/2023
Next Earnings (Estimated)
8/08/2023
Fiscal Year End
12/31/2023
Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Industry
Biological products, except diagnostic
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:INKT
CUSIP
N/A
CIK
1840229
Web
www.minktherapeutics.com
Phone
212-994-8250
Fax
N/A
Employees
33
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$0.00
High Stock Price Forecast
$0.00
Low Stock Price Forecast
$10,000,000.00
Forecasted Upside/Downside
+170.3%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
0 Analysts

Profitability

EPS (Most Recent Fiscal Year)
($0.77)
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
$-27,990,000.00
Net Margins
N/A
Pretax Margin
N/A
Return on Equity
-665.42%
Return on Assets
-109.70%

Debt

Debt-to-Equity Ratio
N/A
Current Ratio
1.38
Quick Ratio
1.38

Sales & Book Value

Annual Sales
N/A
Price / Sales
N/A
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
($0.01) per share
Price / Book
-185.00

Miscellaneous

Outstanding Shares
34,420,000
Free Float
29,875,000
Market Cap
$63.68 million
Optionable
Not Optionable
Beta
-0.60

Key Executives

  • Dr. Garo H. Armen Ph.D. (Age 69)
    Exec. Chairman
  • Dr. Jennifer S. Buell Ph.D. (Age 47)
    Pres, CEO & Director
    Comp: $232.54k
  • Dr. Marcus Antonius van Dijk Ph.D. (Age 60)
    Chief Scientific Officer
  • Ms. Christine M. Klaskin (Age 56)
    Treasurer
    Comp: $20.02k
  • Mr. Patrick N. Jordan M.B.A.
    VP of Bus. Operations
  • Ms. Kimberly Ha
    Head of Investor Relations
  • Ms. Heather Boussios
    Gen. Counsel & Chief Compliance Officer
  • Joy Zhou Ph.D.
    VP & Head of CMC

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions













INKT Stock - Frequently Asked Questions

Should I buy or sell MiNK Therapeutics stock right now?

0 Wall Street analysts have issued "buy," "hold," and "sell" ratings for MiNK Therapeutics in the last twelve months. There are currently for the stock. The consensus among Wall Street analysts is that investors should "n/a" INKT shares.
View INKT analyst ratings or view top-rated stocks.

What is MiNK Therapeutics' stock price forecast for 2023?

0 brokerages have issued 12 month price objectives for MiNK Therapeutics' shares. Their INKT share price forecasts range from $10,000,000.00 to $0.00. On average, they predict the company's share price to reach $0.00 in the next twelve months. This suggests that the stock has a possible downside of 100.0%.
View analysts price targets for INKT or view top-rated stocks among Wall Street analysts.

How have INKT shares performed in 2023?

MiNK Therapeutics' stock was trading at $2.61 at the start of the year. Since then, INKT stock has decreased by 29.1% and is now trading at $1.85.
View the best growth stocks for 2023 here.

Are investors shorting MiNK Therapeutics?

MiNK Therapeutics saw a increase in short interest in the month of May. As of May 15th, there was short interest totaling 180,500 shares, an increase of 70.4% from the April 30th total of 105,900 shares. Based on an average daily trading volume, of 120,600 shares, the short-interest ratio is currently 1.5 days. Approximately 1.9% of the company's shares are sold short.
View MiNK Therapeutics' Short Interest.

When is MiNK Therapeutics' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Tuesday, August 8th 2023.
View our INKT earnings forecast.

How were MiNK Therapeutics' earnings last quarter?

MiNK Therapeutics, Inc. (NASDAQ:INKT) released its quarterly earnings data on Tuesday, March, 21st. The company reported ($0.23) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.21) by $0.02.

What ETFs hold MiNK Therapeutics' stock?

ETFs with the largest weight of MiNK Therapeutics (NASDAQ:INKT) stock in their portfolio include SPDR S&P Biotech ETF (XBI) and Direxion Daily S&P Biotech Bull 3x Shares (LABU).Virtus LifeSci Biotech Clinical Trials ETF (BBC).

When did MiNK Therapeutics IPO?

(INKT) raised $43 million in an initial public offering (IPO) on Friday, October 15th 2021. The company issued 3,333,334 shares at $12.00-$14.00 per share.

What is MiNK Therapeutics' stock symbol?

MiNK Therapeutics trades on the NASDAQ under the ticker symbol "INKT."

Who are MiNK Therapeutics' major shareholders?

MiNK Therapeutics' stock is owned by many different retail and institutional investors. Top institutional investors include First Republic Investment Management Inc. (0.09%). Insiders that own company stock include Agenus Inc, Garo H Armen and Ulf Wiinberg.
View institutional ownership trends.

How do I buy shares of MiNK Therapeutics?

Shares of INKT stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is MiNK Therapeutics' stock price today?

One share of INKT stock can currently be purchased for approximately $1.85.

How much money does MiNK Therapeutics make?

MiNK Therapeutics (NASDAQ:INKT) has a market capitalization of $63.68 million. The company earns $-27,990,000.00 in net income (profit) each year or ($0.77) on an earnings per share basis.

How can I contact MiNK Therapeutics?

The official website for the company is www.minktherapeutics.com. The company can be reached via phone at 212-994-8250 or via email at investor@minktherapeutics.com.

This page (NASDAQ:INKT) was last updated on 6/6/2023 by MarketBeat.com Staff

My Account -